Acadia Pharmaceuticals Target Price

Where could ACAD trade next? Consensus target price: $34.

Get informed when a big investor buys or sells

+ Follow

Share Price

$19.95

Average Target Price

$33.56

68.2% upside

17 analysts in the last 4 months

High: $49 | Low: $14.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-28	William Blair	$33	65.4% upside
2026-09-25	H.C. WainwrightAnanda Ghosh	$33	65.4% upside
2026-09-25	Deutsche BankDavid Hoang	$31	55.4% upside
2026-09-25	BMO Capital	$34	70.4% upside
2026-09-25	NeedhamAmi Fadia	$35	75.4% upside
2026-08-25	Deutsche Bank	$38	90.5% upside
2026-08-25	Morgan Stanley	$28	40.4% upside
2026-08-17	UBS	$49	145.6% upside
2026-08-12	NeedhamAmi Fadia	$41	105.5% upside
2026-08-10	Morgan Stanley	$27	35.3% upside
2026-08-05	RBC CapitalBrian Abrahams	$37	85.5% upside
2026-08-05	OppenheimerMatthew Hershenhorn	$25	25.3% upside
2026-07-29	Raymond James	$14.5	27.3% downside
2026-07-21	BMO Capital	$36	80.5% upside
2026-07-07	RBC CapitalBrian Abrahams	$36	80.5% upside
2026-06-29	Deutsche BankDavid Hoang	$37	85.5% upside
2026-06-29	Canaccord GenuitySumant Kulkarni	$36	80.5% upside
2026-03-02	William Blair	$29	45.4% upside
2026-02-23	Wolfe ResearchRudy Li	$33	65.4% upside
2026-02-23	Mizuho Securities	$35	75.4% upside
2026-02-03	RBC Capital	$31	55.4% upside
2026-01-06	UBSAshwani Verma	$40	100.5% upside
2026-01-05	Needham	$34	70.4% upside
2025-12-16	Piper Sandler	$37	85.5% upside
2025-12-16	Stifel Nicolaus	$37	85.5% upside
2025-12-15	H.C. Wainwright	$37	85.5% upside
2025-12-11	Stifel NicolausPaul Matteis	$25	25.3% upside
2025-12-04	UBSAshwani Verma	$35	75.4% upside
2025-12-02	Mizuho Securities	$29	45.4% upside
2025-09-25	Deutsche Bank	$29	45.4% upside
2025-09-09	UBS	$39	95.5% upside
2025-08-08	UBSAshwani Verma	$36	80.5% upside
2025-06-26	OppenheimerMatthew Hershenhorn	$22	10.3% upside
2025-05-20	Morgan StanleySean Laaman	$24	20.3% upside
2025-05-19	H.C. WainwrightAndrew Fein	$32	60.4% upside
2025-05-19	NeedhamAmi Fadia	$30	50.4% upside
2025-04-28	UBS	$22	10.3% upside
2025-01-03	GuggenheimYatin Suneja	$20	0.3% upside
2024-08-07	Morgan StanleyJeffrey Hung	$20	0.3% upside
2024-06-26	BMO CapitalKeith Tapper	$31	55.4% upside
2024-05-09	H.C. WainwrightAndrew Fein	$27	35.3% upside
2024-05-09	Robert W. BairdJoel Beatty	$28	40.4% upside
2024-05-09	Mizuho SecuritiesUy Ear	$21	5.3% upside
2024-04-30	UBSAshwani Verma	$27	35.3% upside
2024-03-12	UBSAshwani Verma	$33	65.4% upside
2024-03-12	OppenheimerJay Olson	$19	4.8% downside
2024-03-12	NeedhamAmi Fadia	$32	60.4% upside
2024-03-12	Canaccord GenuitySumant Kulkami	$33	65.4% upside
2024-03-12	JMP SecuritiesJason Butler	$39	95.5% upside
2024-01-24	NeedhamAmi Fadia	$37	85.5% upside

Acadia Pharmaceuticals (ACAD) FAQ

Acadia Pharmaceuticals posts a target price of $34. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $34 for ACAD means covering analysts, on average, see the stock 68.2% upside of $19.95 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ACAD's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Acadia Pharmaceuticals's other metric pages and overview cover the third.

Judging Acadia Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $34 here, then scan peer and history charts to see if the gap is persistent.